SABS Stock — SAB Biotherapeutics Inc.: Cash, EV, Pipeline

What they do

Our programs are based on mechanisms of action that have achieved proof-of-concept in clinical trials in indications with significant unmet medical needs. We are focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets or best-in-class against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders.

Source: 10-K FY2025 via SEC EDGAR

Share price

$3.03

Market cap

$275.7M

Cash

$104.0M

Enterprise value

$171.6M

Balance sheet

Cash	$104.0M
Debt	$0.0M
Net cash	$104.0M
Enterprise value	$171.6M
Basic shares	90.1M shares
Fully diluted shares	131.8M shares
Fully diluted market cap	$399.3M
Cash per share	$1.15
Quarterly burn	$9.8M
Cash runway	10.4 quarters

Cash figures as of 2026-09-30. Database snapshot: 2026-11-07.

Share structure

Common

91.0M

Pre-funded warrants

0.0M

Options

39.8M

RSUs

0.0M

Warrants

0.9M

Converts

0.0M

Conv preferred

—

ESPP reserve

0.1M

FDSO

131.8M

Cap table as of 2026-08-03.

Price history

Loading SABS daily closes…

Loading price history…

Next catalyst

High Dose SAB-142 · Dec 13, 2027 - Jan 24, 2028 in 13 mo · Phase 2 · Type 1 Diabetes

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Dec 13, 2027 - Jan 24, 2028 in 13 mo	High Dose SAB-142	Phase 2	Type 1 Diabetes	2H 2027 Est. Sep 30, 2027 · half midpoint

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

SAB-142

Phase 2 · Active Modality: biologic (multi-specific, fully human anti-thymocyte globulin, redosable immunotherapy)

Target multiple immune cells/T lymphocytes

Indications

Stage 3 autoimmune type 1 diabetes (new onset) (Phase 2)

Catalysts

— second half of 2027

Status note Wholly owned lead candidate. Registrational Phase 2b SAFEGUARD study initiated Q3 2025, first patient dosed December 2025, actively enrolling and dosing across the U.S., EU, UK, Australia and New Zealand. Company confirmed with FDA in May 2025 its intent to use SAFEGUARD data as primary evidence for future BLA. Phase 1 in healthy volunteers and T1D patients reported topline results January 2025 and December 2025.

Per-asset detail extracted from the 10-Q filed 2026-08-06. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	High Dose SAB-142
Lead indication	Type 1 Diabetes
Lead phase	Phase 2
Active trials	2
Collaborator trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT07187531	Phase 2	Recruiting	Sponsor	SABS	—	Type 1 Diabetes	2H 2027 Est. Sep 30, 2027 · half midpoint
NCT06435936	Phase 1	Active, not recruiting	Sponsor	SABS	—	PHA1A	—
NCT07670650	Phase 3	Not yet recruiting	Collaborator	University of Florida	—	Type 1 Diabetes (T1D)	—

Sponsor-matched active trials from ClinicalTrials.gov (2 as sponsor, 1 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 3 active trials for SAb Biotherapeutics, Inc. on ClinicalTrials.gov

Specialist fund holders

Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.

Fund	Shares	Q/Q change	% of portfolio	Filing
Vivo Capital	7,299,909	-4,120,091	2.60%	2026-08-14
Perceptive Advisors	6,627,501	+195,758	0.40%	2026-08-14
RA Capital Management	4,401,500	no change	0.15%	2026-08-14
Stonepine Capital	73,271	+23,271	0.22%	2026-08-17

Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Latest news

Loading headlines…

Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.

SABS — SAB Biotherapeutics Inc. ☆

What they do

Balance sheet

Share structure

Price history

Next catalyst

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Specialist fund holders

Latest news

SABS — SAB Biotherapeutics Inc.